Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
暂无分享,去创建一个
L. Kappos | T. Olsson | L. Alfredsson | I. Kockum | M. Khademi | F. Piehl | P. Stridh | P. Benkert | J. Kuhle | C. Barro | D. Leppert | Z. Michalak | J. Lycke | A. Manouchehrinia | Christian Barro
[1] T. Olsson,et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels , 2020, Annals of clinical and translational neurology.
[2] L. Kappos,et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis , 2019, Multiple sclerosis.
[3] F. Piehl,et al. Validation of the Swedish Multiple Sclerosis Register , 2019, Epidemiology.
[4] Ludwig Kappos,et al. Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.
[5] K. Blennow,et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod , 2018, Multiple sclerosis.
[6] X. Montalban,et al. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3‐like 1 and neurofilament light chain , 2018, European journal of neurology.
[7] Markus R. Lange,et al. Predicting risk of secondary progression in multiple sclerosis: A nomogram , 2018, Multiple sclerosis.
[8] Ludwig Kappos,et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis , 2018, Brain : a journal of neurology.
[9] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[10] K. Blennow,et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein , 2017, Neurology.
[11] O. Beiki,et al. Importance of early treatment initiation in the clinical course of multiple sclerosis , 2017, Multiple sclerosis.
[12] Ludwig Kappos,et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.
[13] Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .
[14] K. Blennow,et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis , 2017, Journal of neurochemistry.
[15] K. Blennow,et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis , 2017, Multiple sclerosis.
[16] Henrik Zetterberg,et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.
[17] M. Staufenbiel,et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.
[18] B. Uitdehaag,et al. Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study , 2016, Multiple sclerosis.
[19] M. Ban,et al. Age Related Multiple Sclerosis Severity Score: Disability ranked by age , 2017, Multiple sclerosis.
[20] Cristina Granziera,et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity , 2016, Multiple sclerosis.
[21] L. Alfredsson,et al. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis , 2016, Multiple sclerosis.
[22] Jeffrey A. Cohen,et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.
[23] T. Olsson,et al. Smoking and multiple sclerosis susceptibility , 2013, European Journal of Epidemiology.
[24] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[25] T. Olsson,et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis , 2011, Multiple sclerosis.
[26] J. Salzer,et al. Neurofilament light as a prognostic marker in multiple sclerosis , 2010, Multiple sclerosis.
[27] M. Rovaris,et al. Secondary progressive multiple sclerosis: current knowledge and future challenges , 2006, The Lancet Neurology.
[28] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[29] R. Rigby,et al. Generalized additive models for location, scale and shape , 2005 .
[30] J. Avasarala. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS , 2004, Neurology.
[31] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[32] L. Rosengren,et al. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.
[33] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[34] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[35] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[36] Wei-Yin Loh,et al. Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..